The AMR Action Fund totals approx. $1B USD and has been generated by 23 pharma companies in partnership with the WHO. This fund will focus on treatments for drug resistant infections, a major threat to global health and already responsible for 700,000 deaths per year.

Lloyd Payne PhD, Evotec' s EVP Head of Anti-Infectives Operations, discusses what this funding means for the future of AMR:

https://lnkd.in/dM4EVX5 | info@evotec.com #researchneverstops #AMR #antimicrobialresistance